Cover Image

Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations

Multidrug resistant Gram-negative bacteremia represents a therapeutic challenge clinicians have to deal with. This concern becomes more difficult when causing germs are represented by carbapenem resistant <i>Acinetobacter baumannii</i> or difficult-to-treat <i>Pseudomonas aeruginos...

Full description

Saved in:

Bibliographic Details
Main Authors:	Andrea Marino (Author), Stefano Stracquadanio (Author), Edoardo Campanella (Author), Antonio Munafò (Author), Maria Gussio (Author), Manuela Ceccarelli (Author), Renato Bernardini (Author), Giuseppe Nunnari (Author), Bruno Cacopardo (Author)
Format:	Book
Published:	MDPI AG, 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Oral Fosfomycin Formulation in Bacterial Prostatitis: New Role for an Old Molecule-Brief Literature Review and Clinical Considerations
by: Andrea Marino, et al.
Published: (2022)

<i>Corynebacterium striatum</i> Bacteremia during SARS-CoV2 Infection: Case Report, Literature Review, and Clinical Considerations
by: Andrea Marino, et al.
Published: (2022)

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion
by: Andrea Marino, et al.
Published: (2023)

Ceftazidime-Avibactam Treatment for <i>Klebsiella pneumoniae</i> Bacteremia in Preterm Infants in NICU: A Clinical Experience
by: Andrea Marino, et al.
Published: (2023)

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations
by: Andrea Marino, et al.
Published: (2022)

Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria
by: Marta Palombo, et al.
Published: (2023)

Intravenous Fosfomycin for Systemic Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections
by: Giuseppe Pipitone, et al.
Published: (2023)

Bacterial and Fungal Co-Infections and Superinfections in a Cohort of COVID-19 Patients: Real-Life Data from an Italian Third Level Hospital
by: Manuela Ceccarelli, et al.
Published: (2022)

Long-Term Survivors in a Cohort of People Living with HIV Diagnosed between 1985 and 1994: Predictive Factors Associated with More Than 25 Years of Survival
by: Federica Cosentino, et al.
Published: (2023)

Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat Gram-negative bacterial infections
by: Tasneem A.K. Abdallah, et al.
Published: (2021)

In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains
by: Michela Padovani, et al.
Published: (2023)

Transmission cluster of cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii in cefiderocol-naïve individuals
by: Claudia Alteri, et al.
Published: (2024)

Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies
by: Roberta Maria Antonello, et al.
Published: (2020)

The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy
by: Antonio Anastasia, et al.
Published: (2023)

The Global Burden of Sepsis and Septic Shock
by: Luigi La Via, et al.
Published: (2024)

Effect of Fosfomycin on Cyclosporine Nephrotoxicity
by: Juan Antonio Ortega-Trejo, et al.
Published: (2020)

Detection of Low-Level Fosfomycin-Resistant Variants by Decreasing Glucose-6-Phosphate Concentration in Fosfomycin Susceptibility Determination
by: Guillermo Martín-Gutiérrez, et al.
Published: (2020)

Fosfomycin: Pharmacological, Clinical and Future Perspectives
by: Anneke Corinne Dijkmans, et al.
Published: (2017)

Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant <i>Pseudomonas aeruginosa</i> Bloodstream Infections and/or Hospital-Acquired Pneumonia
by: Milo Gatti, et al.
Published: (2022)

Disc Diffusion and ComASP<sup>®</sup> Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine
by: Gabriele Bianco, et al.
Published: (2023)

Hypernatremia During Intravenous Treatment With Fosfomycin: A Retrospective Medical Record Review Study and an Analysis of Spontaneous Reports in the EudraVigilance Database
by: Cristina Scavone, et al.
Published: (2022)

Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study
by: Gabriele Palermo, et al.
Published: (2023)

Fosfomycin-Overcoming Problematic In Vitro Susceptibility Testing and Tricky Result Interpretation: Comparison of Three Fosfomycin Susceptibility Testing Methods
by: Jan Závora, et al.
Published: (2024)

Fosfomycin Pharmacokinetic Profile in Plasma and Urine and Quantitative Estimation in Prostate and Seminal Vesicles after One and Two Consecutive Doses of Oral Fosfomycin Trometamol in Healthy Male Volunteers
by: Andrea F. D. Di Stefano, et al.
Published: (2022)

Challenges Facing Two Outbreaks of Carbapenem-Resistant <i>Acinetobacter baumannii</i>: From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants
by: Montserrat Rodríguez-Aguirregabiria, et al.
Published: (2024)

The solution to drug resistance of Gram-negative bacteria - Cefiderocol
by: Magdalena Kołodziej, et al.
Published: (2023)

Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms
by: Monirul I. Sajib, et al.
Published: (2023)

Chelation in Antibacterial Drugs: From Nitroxoline to Cefiderocol and Beyond
by: Davorka Repac Antić, et al.
Published: (2022)

Cefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak
by: Giovanna Travi, et al.
Published: (2024)

Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients
by: Noël Zahr, et al.
Published: (2022)

Evaluation of Intravenous Fosfomycin Disodium Dosing Regimens in Critically Ill Patients for Treatment of Carbapenem-Resistant Enterobacterales Infections Using Monte Carlo Simulation
by: Pannee Leelawattanachai, et al.
Published: (2020)

Acute localized exanthematous pustulosis induced by fosfomycin
by: Ibrahim Alfuraih, MD, et al.
Published: (2023)

Fosfomycin: the characteristics, activity, and use in critical care
by: Hashemian SMR, et al.
Published: (2019)

Vascular Graft Impregnation with a Fosfomycin/Oritavancin Combination to Prevent Early Infection
by: Inês Cruz, et al.
Published: (2024)

Fosfomycin: An old antibiotic and new perspectives. A review
by: Marina V. Leonova
Published: (2023)

Fosfomycin Resistance in <i>Escherichia coli</i> Isolates from South Korea and <i>in vitro</i> Activity of Fosfomycin Alone and in Combination with Other Antibiotics
by: Hyeri Seok, et al.
Published: (2020)

Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
by: Stamatis Karakonstantis, et al.
Published: (2022)

Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
by: Cristina Kirkegaard-Biosca, et al.
Published: (2024)

Substance abuse and intimate partner violence: treatment considerations
by: Klostermann Keith C
Published: (2006)

Rediscovering fosfomycin in its 50th anniversary (1969-2019)
by: Pedro Romero Pérez
Published: (2020)